Labcyte receives funding from NCI for biomarker validation program
December 2011

SUNNYVALE, Calif.óLabcyte Inc. recently announced that it received $196,000 from the National Cancer Institute to fund a collaborative cancer biomarker validation program with the Canary Center of Stanford University. The program's goal will be to develop an advanced system for early cancer detection via the integration of a suite of well-established biotechnologies, including Labcyte's acoustic liquid handling for arraying and MALDI mass spectrometry preparation.
"This new project with Labcyte has the potential to accelerate the biomarker validation process dramatically and successfully identify those biomarkers that might be turned into critical early-stage cancer diagnostics," Dr. Mark Stolowitz, director of the Proteomic Core Facility of the Stanford University Canary Center for Cancer Early Detection, said in a press release.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.